MedPath

Fujifilm DBT Plus S-View Versus FFDM Alone in the Detection of Breast Cancer

Completed
Conditions
Breast Cancer
Interventions
Device: DBT plus S-View
Device: FFDM alone
Registration Number
NCT03491917
Lead Sponsor
Fujifilm Medical Systems USA, Inc.
Brief Summary

The purpose of this pilot is to provide credible performance estimate information in order to conduct a subsequent pivotal reader study.

Detailed Description

This clinical research is a retrospective, pilot, multi-reader, multi-case (MRMC) study with an enriched sample of 100 breast screening or diagnostic cases which were selected from the library of mammograms collected under Fujifilm protocol FMSU2013-004A (all subjects previously provided written informed consent agreeing their image data and supporting documentation could be used for future research and investigations). Approximately 6 qualified radiologists will independently perform two reads on all (approximately 100) cases. Each reader will read each case both as a FFDM (Full Field Digital Mammography) read, and a DBT (Digital Breast Tomosynthesis) plus S-View (Synthesized View) read on the ASPIRE Bellus II workstation.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
100
Inclusion Criteria
  • Female subjects participating in FMSU2013-004A protocol with known clinical status
Exclusion Criteria
  • Female subjects that did not have known clinical status in FMSU2013-004A

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
DBT plus S-ViewDBT plus S-ViewBreast images utilizing DBT plus S-View
FFDM aloneFFDM aloneBreast images using FFDM alone only
Primary Outcome Measures
NameTimeMethod
Compare Per Subject Average Area Under the ROC (Receiver Operating Characteristic) Curve (AUC)2 visits with 4 week washout period

Compare per subject average area under the ROC curve (AUC) for DBT (Digital Breast Tomosynthesis) plus S-View (Synthesized View) versus FFDM (Full Field Digital Mammography), based on per-subject POM (probability of malignancy) scores and requiring correct lesion localization. The primary endpoint was non-inferior per-subject average AUC. Statistician estimated AUCs for each reader in each review condition (FFDM, DBT plus S-View) based on per-subject POM scores requiring correct lesion localization. Statistician also calculated for each reader the non-parametric (trapezoidal) AUC for the FFDM read, the DBT plus S-View read, and the difference between them. These AUC's, differences between them, and the associated variance-covariance matrix were obtained using the method of DeLong, et al.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

International HealthCare, LLC

🇺🇸

Norwalk, Connecticut, United States

© Copyright 2025. All Rights Reserved by MedPath